FDA approves Roche’s Susvimo as the first and only continuous …
Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes, affecting more than 29 million adults worldwide. 1-3 ...
FDA approves Roche’s Susvimo as the first and only ... - BioSpace
6 days ago · Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) ... Roche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and has the broadest retina pipeline in ophthalmology, which is led by ...
FDA approves Roche’s Susvimo as the first and only continuous …
6 days ago · F. Hoffmann-La Roche Ltd. Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
FDA Approves Genentech’s Susvimo as the First and Only …
South San Francisco, CA -- February 4, 2025 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes ...
FDA Approves Genentech’s Susvimo as the First and Only …
6 days ago · Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer ... February 04, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX ...
FDA Approves Genentech’s Susvimo as the First and Only
6 days ago · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading …
Roche's Susvimo Approved by U.S. FDA for Treatment of
6 days ago · Roche said that the Food and Drug Administration's decision was based on positive one-year results from the phase III of the Pagoda randomized study, which showed that Susvimo led to sustained ...
Roche to reintroduce Susvimo in the US for people with …
Jul 8, 2024 · The US Food and Drug Administration (FDA) has approved a post-approval supplement to the Biologics License Application for Susvimo, reflecting component-level updates made to the ocular implant and refill needle. Roche will work to make Susvimo available in the US to retina specialists and their patients with nAMD in the coming weeks.
SUSVIMO® (ranibizumab injection) for nAMD and DME
SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor.
Roche | Susvimo (ranibizumab injection)
Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure. Susvimo continuously delivers a customised formulation of ranibizumab over time.
- Some results have been removed